纳米载体
抗药性
医学
癌症
药物输送
药品
化疗
靶向给药
靶向治疗
药理学
内科学
纳米技术
生物
材料科学
微生物学
作者
Fatemeh Davodabadi,Seyedeh Fatemeh Sajjadi,Mohammad Sarhadi,Shaghayegh Mirghasemi,Mahdieh Nadali Hezaveh,Sharareh Khosravi,Mahdieh Kamali Andani,Marco Cordani,Mohsen Basiri,Saeid Ghavami
标识
DOI:10.1016/j.ejphar.2023.176013
摘要
Conventional chemotherapy, one of the most widely used cancer treatment methods, has serious side effects, and usually results in cancer treatment failure. Drug resistance is one of the primary reasons for this failure. The most significant drawbacks of systemic chemotherapy are rapid clearance from the circulation, the drug's low concentration in the tumor site, and considerable adverse effects outside the tumor. Several ways have been developed to boost neoplasm treatment efficacy and overcome medication resistance. In recent years, targeted drug delivery has become an essential therapeutic application. As more mechanisms of tumor treatment resistance are discovered, nanoparticles (NPs) are designed to target these pathways. Therefore, understanding the limitations and challenges of this technology is critical for nanocarrier evaluation. Nano-drugs have been increasingly employed in medicine, incorporating therapeutic applications for more precise and effective tumor diagnosis, therapy, and targeting. Many benefits of NP-based drug delivery systems in cancer treatment have been proven, including good pharmacokinetics, tumor cell-specific targeting, decreased side effects, and lessened drug resistance. As more mechanisms of tumor treatment resistance are discovered, NPs are designed to target these pathways. At the moment, this innovative technology has the potential to bring fresh insights into cancer therapy. Therefore, understanding the limitations and challenges of this technology is critical for nanocarrier evaluation.
科研通智能强力驱动
Strongly Powered by AbleSci AI